



STAR COMBO PHARMA LTD
ABN 38 6157 283 75
171 -177 Woodpark Rd
Smithfield NSW 2164
P: +61 2 9756 6555
sales@starcombo.com.au

28 November 2023

ASX Announcement

Star Combo 2023 AGM – Chairman Update

Attached, please find the business update to be delivered by the Chairman at the Star Combo Pharma Limited 2023 Annual General Meeting held on 28 November 2023 at 11:00am.

Authorised for Release by the Directors

For more information please contact:

Investor and Media relations contact

Su Zhang - CEO

investors@starcombo.com.au

About Star Combo Pharma

Star Combo Pharma Ltd (ASX: S66) is a Sydney based contract manufacturer of vitamins, health and beauty products with a portfolio of own brands and distribution capabilities. Our products are made from natural ingredients with scientific R&D and adheres to the highest manufacturing practices governed by the Therapeutic Goods Administration. Star Combo has offices in China and currently supplies the Australian pharmacy network through 450 Terry White Chemmart stores as well as wholesale customers in Australia and China. Directed by pharmacist and experts in health supplement manufacturing, Star Combo's vision is to be the leading manufacturer of premium vitamins and dietary supplements in Australia. Since its establishment in 2004, Star Combo has demonstrated strong product and business development and continues to expand our current operations to serve our loyal business partners, customers and employees.



STAR COMBO PHARMA LIMITED

Chairman's address

Annual General Meeting

28 November 2023

FY23 Key results



- Group Revenue increased by 7.95% year on year and Group Profit Before Asset write down increased by 153% year on year
- Record OEM production
- Retail Division returns to profit
- Strong cash position at 30 June 2023 and continuing
- Oct 2022 fire impacts closely managed.

Group Financial Performance



	FY23	FY22
	\$000's	\$000's
• OEM Revenue	\$20,729	\$16,177
• Retail Revenue	\$3,947	\$6,672
➤ Group Revenue	\$24,700	\$22,880
➤ (Loss) Before Tax	(\$3,454)	(\$1,081)
➤ Profit before asset write down	\$957	\$377



Record OEM Production



	FY 2023	FY 2022	+/(-) % YOY
Capsules/Tablets Manufactured	520,767,220	507,742,420	3%
Batches Manufactured	306	255	20%
Actual Production Time – Hrs	63,342	57,753	10%
Potential Production Time - Hrs	84,456	77,504	9%
Production OEE	75.0%	74.5%	0.5%

Retail Division returns to Profit



	FY 24 Q1 \$000's	FY 23 H2 \$000's	FY 23 H1 \$000's	FY 23 Full Year \$000's	FY 22 Full Year \$000's
External Sales	758.7	1,615.7	2,331.4	3,947.2	6,672.8
Profit/(Loss) (before Asset Impairment)	18.4	45.7	(266.5)	(220.7)	(659.1)
Asset Impairment					(1,459.4)
Profit/(Loss) after Asset Impairment	18.4	45.7	(266.5)	(220.7)	(2,118.4)

Cash Position



- Strong cash position at 30 June 2023 and continuing
- Full year high level cash flow:
 - Cash and Cash Equivalents at June 2022 \$10.4M
 - Less Capital Expenditure (\$2.7M)
 - Changes in Working Capital \$1.8M
 - Cash and Cash Equivalents at June 2023. \$ 9.5M

Factory Fire Oct 2022



- Oct 2022 fire impacts closely managed to minimise effect on financial and production resources.
- There were no injuries to any person
- Building 2 was significantly damaged.
- Damaged plant within Building 2 was newly installed and was not yet in production.
- Building, plant and contents damage in Building 2 was written off in FY23.
- Write off amount was \$ 4.41M.
- The incident remains the subject of an unsettled insurance claim. Any settlement amount received by Star Combo will be taken as a revenue item of the group P&L when received.

Our people

People

Our team have demonstrated agility and tenacity in guiding the business through the unfortunate fire at the company factory in October 2022 and have continued to execute on our strategy of becoming Australia's leading nutraceutical manufacturer.

Safety

As a manufacturing business, we are dedicated to ensuring we have a safe workplace.

The company has in place a comprehensive occupational health and safety program which all staff are required to follow.

No safety incident has been reported at Star Combo YTD 2023.

Well being

A comprehensive WHS plan has been implemented at Star Combo.

Significant precautions and protocols are in place to safeguard the health and wellbeing of our employees.

OEM Division Update

Manufacturing Division (OEM and Branded)

- OEM division has again performed ahead of expectations with increasing volume of bulk orders manufactured for new customers
- 53 new customer accounts have been established in the last twelve months.
- At the date of this report the group order book for the remainder of FY 2024 is the strongest that it has ever been.
- The following new products have been developed and are available for further commercialisation going forward
 - Gummie line
 - Liquid products
- Continued expansion into new territories with \$1.0M distribution agreement signed with Vietnam based distributor, for supply of Costar products throughout the country

Retail Division Update

- The retail division was significantly impacted by the COVID pandemic and has required some significant restructuring.
- Physical retail stores that the business operated in Carlingford and Ashfield in Sydney were closed in September 2022 with all sales transferred online.
- Newly formed customer service team was established in China to improve customer retention and sales.
- 49% of the business was sold to members of the customer service team in November 2022.
- Modest profits have been achieved every month since the beginning of calendar year 2024 thus providing a significant improvement in the operating profits of the group.

Achievements & Outlook

FY23 Achievements	Continued growth in contract manufacturing division	Operating cash flow positive with \$10.39M in cash in bank	Retail Business restructured
2024 Outlook	Contract manufacturing sector remains main area of strategic focus	Contract manufacturing outlook remains resilient benefiting from strong macro trends	New market development opportunities providing potential for growth
2024 Opportunities	Initialise Gummy line manufacturing capabilities	Commence manufacture of pet supplements, utilising the recently acquired license granted by the Australian Pesticides and Veterinary Medicines Authority (APVMA)	

Investor relations

investors@starcombo.com.au

THANK YOU

DISCLAIMER

STAR COMBO

The information in this presentation is not a prospectus or other form of disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act) and will not be lodged with the Australian Securities and Investments Commission (ASIC). This presentation provides information in summary form and general information regarding Star Combo Pharma Ltd ACN 615 728 375 (Star Combo or the Company) and the proposed placement to sophisticated and professional investors.

This presentation contains information, ideas and analysis which are proprietary to Star Combo. By agreeing to receive this information you also agree to respect the confidential nature of this entire presentation. Specifically you agree not to reproduce in any manner any part of the information contained herein without our prior written consent. This presentation is not complete, is intended only as an outline and has been prepared by and issued by Star Combo to assist in informing interested parties about the Company and should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation.

This presentation is current as at the date on the cover page. The information in this presentation, therefore, remains subject to change. The Company is under no obligation to update the presentation and the information in this presentation remains subject to change by the Company in its absolute discretion and without notice.

This presentation may contain forward looking statements. Whilst the Company has no reason to believe that any such statements are either false, misleading or incorrect, it cannot and does not warrant or guarantee that through either the passage of time or actions beyond the control of the company they will not become so. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This overview of investment does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

The Company's statutory results are prepared in accordance with International Financial Reporting Standards ("IFRS"). This presentation also includes certain non-IFRS measures in presenting the Company's results. Any additional financial information in this presentation which is not included in the Company's 30 June 2018 Financial Statements was not subject to independent audit or review. Investors should be aware that certain financial data included in this presentation is "non-IFRS financial information" under ASIC Regulatory Guide 230: "Disclosing non-IFRS financial information" published by ASIC and may also be "non-GAAP financial information" within the meaning given under Regulation G of the U.S. Securities Exchange Act of 1934, as amended.

Non-IFRS financial information does not have a standardised meaning prescribed by Australian Accounting Standards ("AAS"). Accordingly, the non-IFRS financial information in this presentation: (i) may not be comparable to similarly titled measures presented by other entities; (ii) should not be construed as an alternative to other financial measures determined in accordance with AAS; and (iii) is not a measure of performance, liquidity or value under the IFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial information included in this presentation.

To the maximum extent permitted by law, the Company and its advisers make no representation and give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility and assume no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omissions, from any information, statement or opinion contained in this presentation. All values are expressed in Australian currency unless otherwise stated.

This presentation is not for release to US wire services or distribution in the United States or any country where it may be unlawful. See "International Offer Restrictions".